SCB-420 (aflibercept biosimilar)
/ Sichuan Clover Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 19, 2022
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | N=20 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
March 09, 2022
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1 | N=20 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd | Initiation date: Aug 2021 ➔ Apr 2022
Trial initiation date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
June 09, 2021
Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P1; N=20; Not yet recruiting; Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
Clinical • New P1 trial • Age-related Macular Degeneration • Complement-mediated Rare Disorders • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
1 to 3
Of
3
Go to page
1